<DOC>
	<DOCNO>NCT00033280</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine temozolomide radiation therapy treat patient newly diagnose anaplastic oligodendrogliomas mixed anaplastic oligoastrocytomas .</brief_summary>
	<brief_title>Temozolomide Plus Radiation Therapy Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas Mixed Anaplastic Oligoastrocytomas</brief_title>
	<detailed_description>OBJECTIVES : - Determine rate progression patient newly diagnose anaplastic oligodendrogliomas mixed anaplastic oligoastrocytomas treat neoadjuvant concurrent temozolomide radiotherapy . - Determine toxicity regimen patient . - Determine survival patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord response neoadjuvant temozolomide ( stable disease partial response ( PR ) vs complete response ( CR ) ) . Patients receive oral temozolomide day 1-7 15-21 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients CR PR receive 2 course beyond CR PR . Within 6 week completion neoadjuvant temozolomide , patient stable disease PR undergo radiotherapy 5 day week 6.5 week . Patients also receive oral temozolomide daily 42 day concurrently radiotherapy . Patients CR completion neoadjuvant temozolomide undergo observation . Patients follow 9 12 month , every 4 month 1 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A maximum 37 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm supratentorial pure mixed anaplastic oligodendroglioma Unifocal multifocal disease Prior suspect proven lowgrade glioma eligible provide biopsy reveals pure mixed anaplastic oligodendroglioma previously treat radiotherapy and/or chemotherapy No equivocal oligodendroglial element No tumor predominantly locate posterior fossa ( i.e. , brainstem cerebellum ) No spinal cord tumors No evidence spinal drop metastasis spread noncontiguous meninges PATIENT CHARACTERISTICS : Age : 18 65 Performance status : Zubrod 01 Life expectancy : More 12 week Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 2 time normal Aspartate aminotransferase ( AST ) great 3 time normal Alkaline phosphatase great 2 time normal Renal : Creatinine great 1.5 time normal Other : No active infection No medical problem would preclude study participation No malignancy within past 3 year except carcinoma situ cervix nonmelanoma skin cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior chemotherapy malignancy No prior temozolomide Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy brain , head , neck Surgery : At least 14 day since prior surgery require general anesthesia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
</DOC>